TMDX:NASDAQTransMedics Group, Inc. Analysis
Data as of 2026-08-31 - not real-time
$83.63
Latest Price
8/10Risk
Risk Level: High
Executive Summary
TransMedics Group, Inc. trades at $83.63, with its moving averages tangled rather than clearly stacked — a neutral trend structure. It has gained 13.8% over the past 30 days. Relative strength is 45.9 — neutral — and the MACD signal is bearish. The recent range runs from support at $68.00 up to resistance at $95.18.
The shares look fair, trading on 21.7 times earnings below a sector average of 30.4. Sell-side targets cluster 16.3% above the current quote. Revenue is growing at 20.7% on a 22.7% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 51.0%, a beta of 1.18 and a maximum drawdown of 58.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
The shares look fair, trading on 21.7 times earnings below a sector average of 30.4. Sell-side targets cluster 16.3% above the current quote. Revenue is growing at 20.7% on a 22.7% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 51.0%, a beta of 1.18 and a maximum drawdown of 58.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
Top Market Events
TransMedics Group Inc TMDX posts 21% revenue growth to $190 million, raises full-year guidance, and advances key...TransMedics Group, Inc. previously announced it would report its Q2 2026 results after the market close on August 4,...Yahoo Finance27dTransMedics Group, Inc. TMDX Q2 FY2026 earnings call transcriptTransMedics delivered record Q2 2026...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 105.35
- MACD momentum is negative
- 30-day price change of +13.8%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 21.7 versus sector average of 30.4
- Trading below the 200-day average of 105.35
- Analyst targets imply +16.3% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 21.7 versus sector average of 30.4
- Analyst targets imply +16.3% versus the current price
- Profit margin of 22.7% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth20.70%
Profit Margin22.69%
P/E Ratio21.7
ROE36.29%
ROA4.33%
Debt/Equity167.50
P/B Ratio5.6
Op. Cash Flow$145.9M
Free Cash Flow$44.5M
Industry P/E30.4
Technical Analysis
TrendNeutral
RSI45.9
Support$68.00
Resistance$95.18
MA 20$88.31
MA 50$79.34
MA 200$105.35
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41
Valuation
Fair Value$26.86
Target Price$97.30
Upside/Downside16.35%
GradeFair
TypeGrowth
Risk Assessment
Beta1.18
Volatility50.98%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.